Inspire Advisors LLC Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Inspire Advisors LLC raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 24.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 25,207 shares of the biotechnology company’s stock after acquiring an additional 5,023 shares during the period. Inspire Advisors LLC’s holdings in Exelixis were worth $654,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Fisher Asset Management LLC grew its position in shares of Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 728 shares during the period. V Square Quantitative Management LLC purchased a new stake in Exelixis in the 3rd quarter valued at about $30,000. Rise Advisors LLC acquired a new position in shares of Exelixis during the 1st quarter valued at about $28,000. Park Place Capital Corp purchased a new position in shares of Exelixis during the 2nd quarter worth about $45,000. Finally, GAMMA Investing LLC boosted its position in shares of Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 1,041 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Maria C. Freire sold 8,250 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total value of $219,120.00. Following the transaction, the director now directly owns 91,007 shares of the company’s stock, valued at $2,417,145.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Dana Aftab sold 95,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the sale, the executive vice president now directly owns 520,990 shares of the company’s stock, valued at $13,024,750. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Maria C. Freire sold 8,250 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total value of $219,120.00. Following the transaction, the director now directly owns 91,007 shares in the company, valued at approximately $2,417,145.92. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 327,858 shares of company stock worth $8,640,129 in the last 90 days. 2.85% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EXEL has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, September 18th. Royal Bank of Canada increased their target price on Exelixis from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Wednesday. Bank of America boosted their price target on Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday. Oppenheimer restated an “outperform” rating and issued a $29.00 price objective on shares of Exelixis in a report on Tuesday, July 30th. Finally, Truist Financial reiterated a “buy” rating and set a $33.00 target price (up previously from $32.00) on shares of Exelixis in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.07.

Exelixis Trading Down 0.6 %

EXEL opened at $28.90 on Friday. Exelixis, Inc. has a twelve month low of $18.64 and a twelve month high of $29.75. The firm has a market cap of $8.76 billion, a price-to-earnings ratio of 45.16, a PEG ratio of 0.54 and a beta of 0.54. The company has a fifty day simple moving average of $26.42 and a 200 day simple moving average of $23.83.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The company had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. On average, analysts forecast that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.